By enriching TILs based on CD137 upregulation of TSTs after in vitro stimulation, 27 tumor-specific TCRs were successfully isolated from 6 patients in a clinical study that identified 14 neoantigens expressed by autologous tumor cells, suggesting that the potential of peripheral blood lymphocytes to become true TSTs by introducing recognized TCRs might be realized in the future (17). The gene discussed is TNFRSF9; the disease is neoplasm.